Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13 th Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39 th Annual Healthcare Conference 2021.
| SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13th Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39th Annual Healthcare Conference 2021. “We are pleased to have the opportunity to introduce Second Genome to the many attendees of Biotech Showcase and present the significant advances we have made in developing a product-focused, state-of-the-art platform based on computation and machine learning to drive precision medicine and drug discovery. The microbiome in our bodies has been referred to as a separate organ system and plays an essential role in defining us as individuals in ways similar to our own genes. Its critical influence on our health and on a large number of diseases and disorders, coupled with our ability to exquisitely analyze and mine it, represents significant opportunity for us and our potential partners,” said Karim Dabbagh, PhD, CEO of Second Genome. “It is through the lens of the microbiome that we seek to redefine diseases allowing us to identify potential biomarkers and therapeutics, with our first program expected to enter clinical development for inflammatory bowel disease (IBD) in 2022.” About Second Genome
SOURCE Second Genome |
View original content:
